Among the hypertensive disorders preeclampsia and eclampsia are important causes of mortality and morbidity. Magnesium sulphate is the anticonvulsant of choice for treating eclampsia; more effective than diazepam, phenytoin, or lytic cocktail. Although it is a low cost effective treatment, magnesium sulphate is not available in all low and middle income countries; scaling up its use for eclampsia and severe preeclampsia will contribute to achieving the Millennium Development Goals. Duration of hospital stay is one of the main indicators of the economic impact of any disease process .In the present study we studied the impact of two different modalities of treatments that is magnesium sulphate vs phenytoin for the management of eclampsia and severe preeclampsia(for control of seizures) on the hospital length of stay of the these patients. In our study there was a significant difference in the hospital length of stay in the subgroup treated with magnesium sulphate in comparison to subgroup treated with phenytoin for the control of seizures in eclampsia (p-0.006) and severe preeclampsia(p-0.001).